fda changes semaglutide What's next for Ozempic after the recent warning by FDA? Doctors Petition FDA for Labeling – American Federation of Medical Research

Why brain-based GLP-1 activity matters clinically: It helps explain the appetite-suppressing effects of GLP-1 receptor agonist medications It may contribute to neuroprotective mechanisms being investigated in neurodegenerative diseases It potentially influences cognitive processes and mood regulation, though human evidence remains limited It provides insight into the gut-brain axis and metabolic-neurological interactions Understanding GLP-1's cerebral actions has become particularly relevant as GLP-1 receptor agonistsoriginally developed for type 2 diabetesare now also licensed for weight management in the UK (NICE TA875, TA664)

However, in Malaysia limited study was done on the significance of GSH in influencing the blood glucose level

If you havent experienced meaningful weight loss within the first five months, your current dose might not be sufficient

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

Side Effects Nausea is the most common side effect of both medications, often occurring shortly after a first-time dose or dose increase